Wall Street Analysts See a 379.63% Upside in Cartesian Therapeutics, Inc. (RNAC): Can the Stock Really Move This High?Zacks Investment Research • Tuesday
Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/26
Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T AgreementSeeking Alpha • 10/29/26
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia GravisGlobeNewsWire • 09/29/26
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/26
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease MarketBenzinga • 06/09/26
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune DiseasesGlobeNewsWire • 06/09/26
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027GlobeNewsWire • 05/26/26
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQGlobeNewsWire • 05/12/26
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 04/30/26
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 04/30/26
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/20/26
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptSeeking Alpha • 04/14/26
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/14/26
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of DirectorsGlobeNewsWire • 12/18/25
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?Zacks Investment Research • 10/21/25
Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/09/25